A Bright Spot In Biotech’s Tough Year, Immunocore Looks To Build On Kimmtrak Success
Commercial Success For Orphan Cancer Drug
Immunocore looked set to be another UK biotech disappointment, before it turned around its fortunes with the launch of Kimmtrak. CEO Bahija Jallal talked to Scrip about how she has steered the company to commercial success with its debut product.
